Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05548374
Other study ID # 2022-007-KY
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2023
Est. completion date September 30, 2024

Study information

Verified date February 2023
Source Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Contact Yuanjie Sun
Phone 86 18810337542
Email puzhisun@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is conducted to assess the efficacy and safety of acupuncture in moderate to severe cyclic breast pain.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date September 30, 2024
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Meeting the diagnosis criteria of cyclic breast pain. - Female patients aged between 18 and 55. - Relatively regular menstrual cycle. - Cyclic breast pain lasting for 3 consecutive menstrual cycles or more. - The score of worst pain =5 on Numerical Rating Scale and any level of breast pain lasting 5-21 days during the run-in period of one menstrual cycle. - No previous experience of acupuncture for breast diseases. - Willing to use nonhormonal contraceptives if any risk of pregnancy. - Volunteer to the trial and signing written informed consent. Exclusion Criteria: - Noncyclic breast pain. - Extramammary pain only. - A history of breast cancer or suspicious of malignancy breast disease by examinations. - The Breast Imaging Reporting and Data System (BI-RADS) category 4-6 in ultrasound or mammography examinations. - Combined with mastitis. - Breast pain following injury, surgery, hormones, and/or other drugs. - Usage of hormones (including hormonal contraceptives) in the past three months. - Combined with severe diseases in the cardiac, respiratory, renal, liver, and hematopoietic systems, psychiatric disorder and/or cognitive disorders. - A history of bilateral ovariectomy or premature ovarian failure. - Pregnancy, lactation, or wishing to conceive before the end of the trial. - Poor adherence.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Acupuncture
The acupoints of Shangyintang, Danzhong(RNl7), Jvque(RN14), Liangmen(ST21), Zhongwan(RNl2), Hegu(LI4), Waiguan(SJ5), Zusanli(ST36), Sanyinjiao(SP6), Taichong(LR3) are selected as main acupoints and used per treatment. The other three acupoints will be chosen one each session according to the syndrome differentiation: Taixi (KI3) for liver and kidney deficiency, Fenglong (ST40) for spleen deficiency and phlegm coagulation, and Xuehai (SP10) for qi-stagnation and blood-stasis. Sterile adhesive pads will be placed on the acupoints after skin disinfection. Hwato-brand disposable acupuncture needles (size 0.30×40mm) will be inserted into the acupoints through the adhesive pads. Afterwards, the acupuncture will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes during 30-minute maintenance.
Sham acupuncture
The acupoints of Shangyintang, Danzhong(RNl7), Jvque(RN14), Liangmen(ST21), Zhongwan(RNl2), Hegu(LI4), Waiguan(SJ5), Zusanli(ST36), Sanyinjiao(SP6), Taichong(LR3) are selected as main acupoints and used per treatment. The other three acupoints will be chosen one each session according to the syndrome differentiation: Taixi (KI3) for liver and kidney deficiency, Fenglong (ST40) for spleen deficiency and phlegm coagulation, and Xuehai (SP10) for qi-stagnation and blood-stasis. Sterile adhesive pads will be placed on the acupoints after skin disinfection. The needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrusted and twirled gently for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.

Locations

Country Name City State
China Yuanjie Sun Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Expectance assessment Patients will be asked what do you think the condition of breast pain will be in three menstrual cycles. At the end of Cycle 0 (each cycle is 25-35 days)
Other Assessment of belief in acupuncture Patients will be asked do you think acupuncture can help to treat your breast pain. At the end of the Cycle 0 and Cycle 3 (each cycle is 25-35 days)
Other Blinding assessment Participants will be ask do you think you have received traditional acupuncture in the past 3 menstrual cycles. Within 5 minutes after the last treatment
Other Adherence assessment Adherence will be assessed via counting treatment sessions. Those complete over 80% treatment sessions will be defined as of good adherence. Through the Cycle 1, cycle 2, and cycle 3 (each cycle is 25-35 days)
Other Proportion of participants using rescue medicine. Through study completion, an average of one and a half years.
Other Proportion of participants using concomitant medicine or therapy that might impact breast pain. Through study completion, an average of one and a half years.
Primary The change from baseline in the numerical rating scale (NRS) score on the worst breast pain. Participants will fill in the Cardiff Breast Pain Chart to assess the intensity of worst and average pain daily in the form of NRS score ranging from 0-10. 0 refers to no pain and 10 refers to the worst pain imaginable. The highest NRS score on the worst breast pain during the cycle is defined as the final score on the worst pain. Through the Cycle 3 (each cycle is 25-35 days)
Secondary The change from baseline in the numerical rating scale (NRS) score on the worst breast pain. Participants will fill in the Cardiff Breast Pain Chart to assess the intensity of worst and average pain daily in the form of NRS score ranging from 0-10. 0 refers to no pain and 10 refers to the worst pain imaginable. The highest NRS score on the worst breast pain during the cycle is defined as the final score on the worst pain. Through the Cycle 1, Cycle 2, Cycle 6 and Cycle 9 (each cycle is 25-35 days)
Secondary The change from baseline in the numerical rating scale (NRS) score on the average breast pain. Participants will fill in the Cardiff Breast Pain Chart to assess the intensity of worst and average pain daily in the form of NRS score ranging from 0-10. 0 refers to no pain and 10 refers to the worst pain imaginable. The average NRS score on the average breast pain during the cycle is defined as the mean of the average pain score during the cycle. Through the Cycle 1, Cycle 2, Cycle 3, Cycle 6 and Cycle 9 (each cycle is 25-35 days)
Secondary Proportion of participants with at least 50% reduction of NRS score on the worst breast pain. Participants will fill in the Cardiff Breast Pain Chart to assess the intensity of worst and average pain daily in the form of NRS score ranging from 0-10. 0 refers to no pain and 10 refers to the worst pain imaginable. The highest NRS score on the worst breast pain during the cycle is defined as the final score on the worst pain. Through the Cycle 1, Cycle 2, Cycle 3, Cycle 6 and Cycle 9 (each cycle is 25-35 days)
Secondary Proportion of participants with at least 50% reduction of NRS score on the average breast pain. Participants will fill in the Cardiff Breast Pain Chart to assess the intensity of worst and average pain daily in the form of NRS score ranging from 0-10. 0 refers to no pain and 10 refers to the worst pain imaginable. The average NRS score on the average breast pain during the cycle is defined as the mean of the average pain score during the cycle. Through the Cycle 1, Cycle 2, Cycle 3, Cycle 6 and Cycle 9 (each cycle is 25-35 days)
Secondary The change from baseline in the number of days with a NRS score of 5 or over on the worst breast pain. Participants will fill in the Cardiff Breast Pain Chart to assess the intensity of worst and average pain daily in the form of NRS score ranging from 0-10. 0 refers to no pain and 10 refers to the worst pain imaginable. The highest NRS score on the worst breast pain during the cycle is defined as the final score on the worst pain. Through the Cycle 1, Cycle 2, Cycle 3, Cycle 6 and Cycle 9 (each cycle is 25-35 days)
Secondary The change from baseline in the number of days with breast pain. Participants will fill in the Cardiff Breast Pain Chart to assess the intensity of worst and average pain daily in the form of NRS score ranging from 0-10. 0 refers to no pain and 10 refers to the worst pain imaginable. Through the Cycle 1, Cycle 2, Cycle 3, Cycle 6 and Cycle 9 (each cycle is 25-35 days)
Secondary The proportion of patients reported "very much improved" or "much improved" per the Patient Global Impression of Change (PGIC). PGIC is a 7-point scale reflecting patient's self-rating of overall improvement: "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse" or "very much worse". At the end of the Cycle 3, Cycle 6 and Cycle 9 (each cycle is 25-35 days)
Secondary The impact of breast pain on sexual life, daily life, mood and sleep rated by NRS scale. NRS ranges from 0 to 10, with 0 indicating no impact and 10 indicating influence completely, and higher scores represent severer impact. At the end of the Cycle 1, Cycle 2, Cycle 3, Cycle 6 and Cycle 9 (each cycle is 25-35 days)
Secondary The change from baseline in the Sort Form 12-item Health Survey (SF-12). The SF-12 is a general health questionnaire consisting of 12 questions. It investigates the patient's state of health via 8 different dimensions of general health perception, physical health, limited physical role function, physical pain, vitality, mental health, limited emotional role function, and social functioning. The sores of SF-12 range from 0 to 100, with higher scores indicating better physical and mental health functioning. At the end of the Cycle 1, Cycle 2, Cycle 3, Cycle 6 and Cycle 9 (each cycle is 25-35 days)
Secondary The change from baseline in the total and sub scores of Hospital Anxiety and Depression Scale (HADS). HADS consists of 14 items, which are divided into two 7-item subscales to reflect a state of generalized anxiety and the depression. The respondent rates each item on a 4-point scale ranging from 0 (absence) to 3 (extreme presence). The total scores of HADS ranges from 0 to 42, with higher scores indicating severer symptoms. At the end of the Cycle 1, Cycle 2, Cycle 3, Cycle 6 and Cycle 9 (each cycle is 25-35 days)
See also
  Status Clinical Trial Phase
Completed NCT03391986 - Acupuncture for Pain Management During Uterine Aspiration N/A
Recruiting NCT05528263 - Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial) N/A
Active, not recruiting NCT06070090 - Tapping in Together: A Pilot Study on Group Acupuncture for Ketamine Experience Integration N/A
Completed NCT03627533 - The Differences of Oocyte Maturation, Granulosa Cell Apoptosis Index Between Electroacupuncture And Sham Groups IVF N/A
Not yet recruiting NCT05794633 - Acupuncture Therapy in Patients With Subacromial Impingement Syndrome N/A
Recruiting NCT06001112 - Immediate Analgesic Effects of Cheek Acupuncture for Acute Gouty Arthritis N/A
Completed NCT04844710 - The Effects of Acupuncture in Overcoming Inflammatory Response to COVID-19 Mild-moderate Symptoms N/A
Active, not recruiting NCT04048941 - One Needle Hand Acupuncture for MSK Disorders N/A
Completed NCT04759079 - The Effects of Acupuncture Against Postoperative Nausea and Vomit After Laparoscopic Cholecystectomy N/A
Completed NCT03299439 - Acupuncture Treatment for Knee Osteoarthritis With Sensitive Acupoints and Tender Points N/A
Not yet recruiting NCT05537155 - Buccal Acupuncture for Delirium Treatment in Older Patients Recovering From Orthopedic Surgery N/A
Completed NCT03008668 - A Pilot Trial of Acupuncture for Knee Osteoarthritis With Differential Functional Status of Acupoints N/A
Completed NCT01283477 - Efficacy of Acupuncture for Prophylaxis of Intrathecal Morphine Induced Pruritis in Patients Undergoing Caesarean Delivery N/A
Recruiting NCT06042465 - Investigation on Efficacy Between TCM Treatment Using Acupuncture and Tui-na With Physiotherapy on Patellofemoral Pain Syndrome N/A
Recruiting NCT05516862 - Determining the Right Acupuncture for Good Recovery Over Neuropsychiatric Trauma N/A
Completed NCT03633097 - Efficacy and Safety of Acupuncture Treatment as an Adjunctive Therapy After Knee Replacement N/A
Active, not recruiting NCT05938660 - Effects of Acupressure at Sanyinjiao Point on Primary Dysmenorrhea Among University Students. N/A
Not yet recruiting NCT02597530 - Different Stimuli of Transcutaneous Electric Acupoint Stimulation(TEAS) on Acupuncture Anesthesia N/A
Recruiting NCT04249921 - Evaluation of Acupuncture Effects for Complications After Surgery of Cerebellopontine Angle Tumor in Skull Base
Recruiting NCT05521737 - Effect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy N/A